In January 2010, Andrew Witty realized that the Pharmaceutical Patent Pool in and of itself was insufficient to generate action on neglected tropical diseases. He announced, therefore the "Open Labs, Open Minds" strategy. Was this enough to encourage action for neglected diseases affecting the world's poorest? How would GSK's shareholders react?
看看哪些人也有訂購?